- /
- Supported exchanges
- / AS
- / GLPG.AS
Galapagos N.V. (GLPG AS) stock market data APIs
Galapagos N.V. Financial Data Overview
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that is in phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Galapagos N.V. (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Galapagos N.V. data using free add-ons & libraries
Get Galapagos N.V. Fundamental Data
Galapagos N.V. Fundamental data includes:
- Net Revenue: 1 044 M
- EBITDA: 663 M
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-05-06
- EPS/Forecast: -0.5052
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Galapagos N.V. News
New
Lakefront Biotherapeutics NV (AMS:LKFT) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
Lakefront Biotherapeutics NV (AMS:LKFT) last week reported its latest quarterly results, which makes it a good time for investors to dive in and see if the business is performing in line with expectat...
Galapagos Reports First Quarter 2026 Financial Results and Provides Business Update
Galapagos NV Galapagos’ name change to Lakefront Biotherapeutics approved at the Company’s EGM (Euronext & NASDAQ: LKFT) Collaboration Agreement with Gilead to advance potential First and Be...
Galapagos’ Shareholders Adopt All Resolutions Proposed by the Board of Directors at the Annual and Extraordinary Shareholders’ Meetings 2026
Galapagos NV Mechelen, Belgium; April 28, 2026, 22:01 CET — Galapagos NV (Euronext & NASDAQ: GLPG) today announces that all resolutions proposed at the Company’s Annual and Extraordinary Sharehol...
RBC Cuts Galapagos NV (GLPG) Price Target to $28, Maintains Sector Perform Ahead of Q1
We recently compiled a list of the 9 Most Undervalued Healthcare Stocks to Buy Now. Galapagos NV is among the most undervalued stocks to invest in. TheFly reported on April 7 that RBC Capital Markets...
Corporate Events Calendar & News package for
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.